Lysophosphatidic acid enhances collagen deposition and matrix thickening in engineered tissue

Journal of Tissue Engineering and Regenerative Medicine

Volumn 9, Issue 11, 2015, Pages E65-E75

  Chabaud, Stéphane ^a   Marcoux, Thomas Louis ^a   Deschênes Rompré, Marie Pier ^a   Rousseau, Alexandre ^a   Morissette, Amélie ^a   Bouhout, Sara ^a   Bernard, Geneviève ^a   Bolduc, Stéphane ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Collagen; L arginine; Lysophosphatidic acid; Matrix

Indexed keywords

CELL CULTURE; CELLS; COLLAGEN; DEPOSITION RATES; ENZYME ACTIVITY; PHOSPHOLIPIDS; POSITIVE IONS; SELF ASSEMBLY; TISSUE;

ASSEMBLY APPROACH; BIOLOGICAL CELLS; BIOLOGICAL FUNCTIONS; COLLAGEN DEPOSITION; COLLAGEN MATRICES; CULTURE SUPERNATANT; ENGINEERED TISSUES; L-ARGININE; LYSOPHOSPHATIDIC ACID; MATRIX;

ARGININE;

ALPHA SMOOTH MUSCLE ACTIN; ARGININE; COLLAGEN TYPE 1; FIBRONECTIN; LYSOPHOSPHATIDIC ACID; PROTEIN ZO1; UROPLAKIN 2; COLLAGEN; CULTURE MEDIUM; LIPID; LYSOPHOSPHOLIPID;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL ELONGATION; CELL MEMBRANE RESISTANCE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; TISSUE ENGINEERING; BIOPSY; CADAVER; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; FIBROBLAST; FLUORESCENCE MICROSCOPY; METABOLISM; PATHOLOGY; PHENOTYPE; PROCEDURES; SKIN; UROTHELIUM;

ARGININE; BIOPSY; CADAVER; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; CULTURE MEDIA; EPITHELIAL CELLS; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBRONECTINS; HUMANS; LIPIDS; LYSOPHOSPHOLIPIDS; MICROSCOPY, FLUORESCENCE; PHENOTYPE; SKIN; TISSUE ENGINEERING; UROTHELIUM;

EID: 84946094670     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1711     Document Type: Article

References (36)

1. Atala A, Bauer S, Soker B et al. 2006; Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 367(9518): 1241-1246.
2. Auger FA, Berthod F, Moulin VR et al. 2004; Tissue-engineered skin substitutes: from in vitro constructs to in vivo applications. Biotechnol Appl Biochem 39(Pt 3): 263-275.
3. Auger FA, Lopez CA, Valle R et al. 1995; Skin equivalent produced with human collagen. In Vitro Cell Dev Biol Anim 31(6): 432-439.
4. Bandoh K, Aoki J, Hosono H et al. 1999; Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem 274(39): 27776-27785.
5. Bouhout S, Perron E, Gauvin R et al. 2010a; In vitro reconstruction of an autologous, watertight, and resistant vesical equivalent. Tissue Eng Part A 16(5): 1539-1548.
6. Bouhout S, Ouellet G, Perron E et al. 2010b; Evolution in tissue engineering for the lower urinary tract. In Tissue engineering, Eberli D (ed.). IN-TECH Vienna, Austria; p. 485.
7. Carrier P, Deschambeault A, Audet C et al. 2009; Impact of cell source on human cornea reconstructed by tissue engineering. Invest Ophthalmol Vis Sci 50(6): 2645-3652.
8. Castelino FV, Seiders J, Bain G et al. 2011; Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma. Arthritis Rheum 63(5): 1405-1415.
9. Chevalley T, Rizzoli R, Manen D et al. 1998; Arginine increases insulin-like growth factor-I production and collagen synthesis in osteoblast-like cells. Bone 23(2): 103-109.
10. Choi JW, Herr DR, Noguchi K et al. 2010; LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-186.
11. Corriveau MP, Boufaied I, Lessard J et al. 2009; The fibrotic phenotype of systemic sclerosis fibroblasts varies with disease duration and severity of skin involvement: reconstitution of skin fibrosis development using a tissue engineering approach. J Pathol 217(4): 534-542.
12. Delmonico FL, Cosimi AB, Russell PS. 1981; Temporary skin transplantation for the treatment of extensive burns. Ann Clin Res 13(4-5): 373-381.
13. Desmouliere A, Chaponnier C, Gabbiani G. 2005; Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13(1): 7-12.
14. Germain L, Rouabhia M, Guignard R et al. 1993; Improvement of human keratinocyte isolation and culture using thermolysin. Burns 19(2): 99-104.
15. Hynes RO. 2009; The extracellular matrix: not just pretty fibrils. Science 326(5957): 1216-1219.
16. Im DS, Heise CE, Harding MA et al. 2000; Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate. Mol Pharmacol 57(4): 753-759.
17. Jean J, Lapointe M, Soucy J et al. 2009; Development of an in vitro psoriatic skin model by tissue engineering. J Dermatol Sci 53(1): 19-25.
18. Karliner JS. 2002; Lysophospholipids and the cardiovascular system. Biochim Biophys Acta 1582: 216-221.
19. Ley K, Zarbock A. 2008; From lung injury to fibrosis. Nat Med 14(1): 20-21.
20. L'Heureux, N, Stoclet JC, Auger F et al. 2001; A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses. FASEB J 15(2): 515-524.
21. Magnan M, Berthod F, Champigny MF et al. 2006; In vitro reconstruction of a tissue-engineered endothelialized bladder from a single porcine biopsy. J Pediatr Urol 2(4): 261-270.
22. McDonald JA. 1988; Extracellular matrix assembly. Annu Rev Cell Biol 4: 183-207.
23. Mills GB, Moolenaar WH. (2003). The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591
24. Nakagawa H, Ikeda H, Nakamura K et al. 2011; Autotaxin as a novel serum marker of liver fibrosis. Clin Chim Acta 412(13-14): 1201-1206.
25. Pages C, Simon MF, Valet P et al. 2001; Lysophosphatidic acid synthesis and release. Prostaglandins Other Lipid Mediat 64(1-4): 1-10.
26. Panetti TS, Magnusson MK, Peyruchaud O et al. 2001; Modulation of cell interactions with extracellular matrix by lysophosphatidic acid and sphingosine 1-phosphate. Prostaglandins 64(1-4): 93-106.
27. Paquette JS, Moulin V, Tremblay P et al. 2004; Tissue-engineered human asthmatic bronchial equivalents. Eur Cell Mater 7: 1-11.
28. Parizi M, Howard EW, Tomasek JJ. 2000; Regulation of LPA-promoted myofibroblast contraction: role of Rho myosin light chain kinase, and myosin light chain phosphatase. Exp Cell Res 254: 210-220.
29. Pradere JP, Gonzalez J, Klein J et al. 2008; Lysophosphatidic acid and renal fibrosis. Biochim Biophys Acta 1781(9): 582-587.
30. Rancoule C, Pradère JP, Gonzalez J et al. 2011; Lysophosphatidic acid-1-receptor targeting agents for fibrosis. Expert Opin Investig Drugs 20(5): 657-667.
31. Robayo LM, Moulin VJ, Tremblay P et al. 2011; New ligament healing model based on tissue-engineered collagen scaffolds. Wound Repair Regen 19(1): 38-48.
32. Rouabhia M, Germain L, Auger FA. 1993; Cultured epithelium for skin trauma treatment: clinical and experimental studies. Transplant Proc 25(3): 2348-2349.
33. Simon F, Bergeron D, Larochelle S et al. 2012; Enhanced secretion of TIMP-1 by human hypertrophic scar keratinocytes could contribute to fibrosis. Burns 38(3): 421-427.
34. Wittmann F, Prix N, Mayr S et al. 2005; L-arginine improves wound healing after trauma-hemorrhage by increasing collagen synthesis. J Trauma 59(1): 162-168.
35. Xu Y, Shen Z, Wiper DW. 1998; Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280(8): 719-723.
36. Ye X, Chun J. 2010; Lysophosphatidic acid (LPA) signalling in vertebrate reproduction. Trends Endocrinol Metab 21(1): 17.